Comprehensive Cancer Centers is expanding its community-based clinical trials with the announcement of a collaboration with Sarah Cannon Research Institute.
Comprehensive Cancer Centers, through its affiliation with The US Oncology Network, recently expanded its Southern Nevada clinical trials with the announcement of a collaboration with Sarah Cannon Research Institute (SCRI). SCRI is one of the world’s leading oncology research organizations conducting community-based clinical trials. This collaboration will be known as “SCRI at Comprehensive Cancer Centers” and will expand access to innovative cancer treatments for patients across Henderson, Las Vegas, and Southern Nevada.
The collaboration with SCRI offers several advantages for cancer patients:
- Greater Treatment Options: Eligible patients will have access to a wider range of clinical trials, offering options based on their individualized treatment plan.
- Access to Cutting-Edge Therapies: Eligible patients will have the opportunity to participate in trials evaluating the latest advancements in cancer research.
- Advanced Clinical Trial Matching: Comprehensive will leverage SCRI’s Personalized Medicine Team and Genospace, a highly specific trial matching technology that uses clinical and genetic data to help identify individualized trial opportunities for patients.
Who Is Sarah Cannon? History of the Sarah Cannon Research Institute (SCRI)To understand the impact of the institute, one must first look to the woman who gave it her name. Sarah Cannon was known to millions of radio and television fans around the globe by her stage persona, Minnie Pearl. With her signature straw hat, hanging price tag, and cheerful demeanor, she was a cornerstone of the Grand Ole Opry and a symbol of rural American warmth. Behind the stage makeup, however, Sarah Cannon was a woman of fierce intellect and deep compassion.
In the early 1990s, Sarah faced aggressive breast cancer and received treatment at a founding center in Nashville under the care of oncologists Dr. Anthony Greco and Dr. John Hainsworth. Grateful for the exceptional care she received, Cannon realized that many people lacked the resources to seek out specialized cancer centers. Before her death, she offered her real name to her physicians with a clear, singular mandate: use it to advance cancer research and patient education, ensuring that everyday people could access advanced medical care close to home. By 2004, through a joint venture with HCA Healthcare, the entity was formally established as the Sarah Cannon Research Institute.
The history of the Sarah Cannon Research Institute is a testament to what happens when scientific excellence is paired with democratization. What began as a localized effort in Nashville has grown into a global powerhouse that manages a massive patient-centric clinical trial organization, including a comprehensive Contract Research Organization (CRO) division that guides drug development from corporate concept to final regulatory approval.
By fulfilling Sarah Cannon’s final wish, the institute did something far grander than simply building laboratories; it redefined the geography of hope. It proved that world-class science does not belong exclusively behind the ivory towers of academia. Because of SCRI, the next great breakthrough in cancer care is just as likely to be discovered, tested, and delivered to a patient in a clinic, such as Comprehensive Cancer Centers, as it is in a sprawling metropolitan university hospital.
For generations, the landscape of cutting-edge cancer care was defined by geography. If a patient sought access to the newest, highly experimental, and potentially life-saving oncology drugs, they had to travel to university-affiliated academic medical centers located in major metropolitan areas. For millions of people living in rural or suburban communities, the financial, physical, and emotional toll of traveling hundreds of miles for weekly clinical trial appointments was an insurmountable barrier.
In the early 1990s, in Nashville, driven by the vision of forward-thinking oncologists and a beloved American cultural icon, an organization emerged that would bring the highest tier of clinical drug development directly into the neighborhoods where patients lived. Today, the Sarah Cannon Research Institute (SCRI) stands as one of the world’s premier clinical research organizations, having orchestrated a monumental shift in how cancer drugs are tested, approved, and administered globally.
The foundational innovation of SCRI was not a specific molecule or lab technique, but an operational philosophy. The founders asked a radical question: Why should the patient travel to the research, when the research can travel to the patient? Statistically, the vast majority of cancer patients, roughly 85%, receive their diagnoses and subsequent treatments at local, community-based hospitals and private oncology practices rather than major academic universities. Yet, historically, only a tiny fraction of these community patients had access to clinical trials. SCRI expanded access to community-based oncology clinical trials by building an intricate, highly sophisticated infrastructure that allowed local community physicians to operate as primary investigators for complex clinical trials.
By providing community practices with centralized regulatory support, robust data management, strict safety monitoring, and direct access to pharmaceutical sponsors, SCRI transformed everyday clinics into high-powered research hubs. This model significantly accelerated patient enrollment. In traditional academic settings, filling a clinical trial cohort can take months or years due to geographic constraints. SCRI’s vast, decentralized footprint meant they could identify eligible patients across dozens of states simultaneously, bringing new drugs to the testing phase at unprecedented speeds.
While many community research networks limit their scope to late-stage, Phase III clinical trials, SCRI took an incredibly bold leap by establishing the first dedicated, non-academic drug development program focused heavily on Phase I and first-in-human studies. Phase I trials represent the absolute cutting edge of pharmacology. They are the initial tests where a completely new compound is introduced to human subjects to determine safety, appropriate dosage, and metabolic behavior. These trials require an extraordinary level of scientific oversight, precise medical writing, and instantaneous safety reporting. SCRI excelled in this high-intensity environment. To date, the institute has conducted more than 900 first-in-human clinical trials. Through its network of hundreds of research sites spanning more than 20 states and reaching across the Atlantic into the United Kingdom, SCRI became the preferred partner for biotechnology and pharmaceutical companies looking to advance their most promising oncology assets from the lab bench to the patient bedside.
The true measure of a research institute’s impact lies in cancer treatment outcomes and survival rates. On this front, the legacy of the Sarah Cannon Research Institute is woven into the very fabric of modern oncology.
Over the last decade, SCRI has been a pivotal clinical trial leader in the vast majority of cancer therapies approved by the United States Food and Drug Administration (FDA). Whether looking at breakthrough immunotherapies that train the body’s own immune system to hunt down malignant cells, or highly specific targeted therapies that disable the genetic mutations driving tumor growth, SCRI’s investigators and patients have been at the center of the data collection.
This immense volume of research means that thousands of patients who had exhausted all standard, commercially available treatment options were able to access next-generation therapies years before they hit the open market. For these individuals, the community-based trials offered by SCRI were not just scientific experiments; they were immediate lifelines.
As oncology moved into the 21st century, the science of cancer care shifted from treating a disease based solely on its anatomical location, such as lung, breast, or colon cancer, to treating it based on its unique genetic and molecular profile. SCRI adapted swiftly to this era of precision medicine.
When a patient enters an SCRI-affiliated clinic, their tumor’s DNA can be sequenced to identify specific biomarkers. The institute’s vast digital infrastructure then scans its massive portfolio of open clinical trials to match that specific patient with a targeted drug designed specifically for their tumor’s genetic signature. This eliminates the heartbreaking guesswork of traditional trial-and-error oncology.
Locally in Southern Nevada, Comprehensive Cancer Centers has evolved into one of the region’s most established oncology providers. The practice was built on the idea of bringing advanced cancer care into the community, uniting specialties and services under one coordinated model. Today, its physicians work closely with leading national research networks and institutions, helping translate breakthrough science into accessible treatment options for local patients. That longstanding emphasis on research-driven care has allowed Comprehensive to play a role in the development of more than 120 FDA-approved therapies.
This relationship between Comprehensive Cancer and SCRI highlights Comprehensive’s dedication to providing the most advanced, personalized cancer care close to home, which closely aligns with the vision Sarah Cannon herself had when she helped launch the program.
Comprehensive Cancer Centers Can Help
Physicians at Comprehensive Cancer Centers provide a variety of treatment options for patients with all treatments being done in Southern Nevada. To schedule an appointment, please call 702-952-3350.
The content in this post is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of qualified health providers with questions you may have regarding medical conditions.